Top Story

Lung cancer clinical trials routinely exclude cancer survivors

October 31, 2014

Many patients are automatically excluded from lung cancer clinical trials due to previous cancer, according to findings.

Additionally, this criterion appears to be used in trials with a variety of characteristics, including more than two-thirds of trials with non-survival endpoints, the researchers wrote.

In the Journals

Longer course of first-line therapy provided no survival benefit in NSCLC

October 29, 2014
Patients with advanced non–small cell lung cancer treated with six cycles of platinum-based therapy demonstrated no survival advantage compared with those who…
figure FDA News

FDA grants breakthrough therapy designation to Keytruda for NSCLC

October 27, 2014
The FDA has issued breakthrough therapy designation to pembrolizumab for treating patients with epidermal growth factor receptor mutation-negative and anaplastic…
figure Meeting News Coverage

Targeted treatments for lung cancer likely to drive field forward

October 17, 2014
WASHINGTON — Recent progress in the use of genomics to treat lung cancer is likely to advance the field of cancer treatment, according to Mark G. Kris, MD
CME
figure

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »

Filter By:

figure In the Journals

Lung cancer clinical trials routinely exclude cancer survivors

October 31, 2014
Many patients are automatically excluded from lung cancer clinical trials due to previous cancer, according to findings.Additionally, this criterion…
In the Journals

Longer course of first-line therapy provided no survival benefit in NSCLC

October 29, 2014
Patients with advanced non–small cell lung cancer treated with six cycles of platinum-based therapy demonstrated no survival advantage compared…
figure FDA News

FDA grants breakthrough therapy designation to Keytruda for NSCLC

October 27, 2014
The FDA has issued breakthrough therapy designation to pembrolizumab for treating patients with epidermal growth factor receptor mutation-negative…
figure Meeting News Coverage

Targeted treatments for lung cancer likely to drive field forward

October 17, 2014
WASHINGTON — Recent progress in the use of genomics to treat lung cancer is likely to advance the field of cancer treatment, according to…
In the Journals

Medicare reimbursement policy failed to significantly reduce chemotherapy cost

October 16, 2014
The Medicare Prescription Drug, Improvement and Modernization Act of 2003, intended to slow the skyrocketing costs of drugs the federal government…
Meeting News Coverage Perspective

Physician tumor board participation linked to clinical trial enrollment

October 14, 2014
Patients with lung or colorectal cancers whose physicians attended weekly multidisciplinary tumor board meetings were more likely to enroll in…
In the Journals

ASCO: Offer EGFR, ALK testing to all patients with lung adenocarcinoma

October 13, 2014
ASCO today endorsed a joint clinical practice guideline from three other entities that addresses questions about the appropriate use of…
In the Journals

E-cigarettes unhelpful for smoking cessation among patients with cancer

October 13, 2014
A study of patients with cancer who smoke showed those who used electronic cigarettes were more nicotine-dependent than nonusers.Those who used…
Institution Notes

UPCI appoints co-director of lung cancer program

October 12, 2014
James Herman, MD, has been named co-leader of the University of Pittsburgh Cancer Institute’s lung cancer program.Herman, a leader in the…
Institution Notes

Meridian appoints medical director for thoracic oncology

October 7, 2014
Meridian Cancer Care appointed Thomas Lee Bauer II, MD, as its medical director for thoracic oncology.Bauer will be based at Jersey Shore University…
More Headlines »